---
title: "Solengepras: Parkinson's Drug Pipeline"
description: "An experimental non-dopamine pill being tested as an add-on to reduce \"off\" time in Parkinson's. A Phase 3 trial is running; whether it helps is not yet known."
canonical_url: "https://parkinsonspathways.com/pipeline/solengepras-gpr6"
development_stage: "Phase 3: large human trials"
last_updated: 2026-08-07
source: "Parkinson's Pathways"
---
# Solengepras

**Stage:** Phase 3 (ongoing)  ·  **Type:** Symptomatic

**Developer:** Cerevance

**How it works:** A once-daily pill that works outside the dopamine system, dialing down a brain receptor (GPR6) involved in movement, in the hope of smoothing out motor symptoms without adding more dopamine.

**Target:** GPR6 receptor (non-dopaminergic)

**Who it's for:** People with Parkinson's who have motor fluctuations ("off" time) despite taking levodopa; being tested as an add-on.

**Key trials:** NCT06553027

**Last reviewed:** 2026-08-07


## What it is

Almost all Parkinson's medicines work by boosting or mimicking dopamine, which eventually leads to wearing-off and dyskinesia. Solengepras takes a different route: it blocks a receptor called GPR6 that is active in movement circuits, aiming to improve symptoms through a separate pathway. The hope is a smoother response with fewer dopamine-related complications.

## Where it stands

It is being studied in a Phase 3 trial (about 330 people) as an add-on to existing Parkinson's medication, taken once daily at 75 mg or 150 mg versus placebo over 12 weeks. Enrollment has completed and results are expected later; nothing is proven yet.

## What the data shows so far

The Phase 3 add-on trial measures change in daily "off" time. Non-dopaminergic approaches to Parkinson's have a mixed track record, and this drug's earlier work is not enough to say it works. The pre-specified Phase 3 results, when reported, are what will matter, not company summaries or subgroup readouts.

## What families should know

This is a symptomatic treatment aimed at smoothing out good and bad periods, not a disease-modifier and not a cure. It is experimental, not approved, and its main efficacy read-out is still pending.

## Caveats

Not approved and not yet shown to work; pivotal Phase 3 results are still pending. It is an add-on for symptom control, not a treatment that slows the disease. New drug classes often disappoint in Phase 3, so cautious expectations are warranted.

## Timeline

_Most recent first._

- **2026**, Enrollment completed; efficacy results awaited.
- **2024**, Phase 3 add-on trial (NCT06553027) begins enrolling.

## Sources

- [Phase 3 trial on ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06553027)

_Last reviewed: 2026-08-07._

## More

- [Back to the Parkinson's drug pipeline](https://parkinsonspathways.com/pipeline)
- [Browse all recruiting trials](https://parkinsonspathways.com/trials)